DiBiase Mary
SEC insider (Form 3/4/5 filer). CIK 0001880179. Chief Operating Officer at X4 Pharmaceuticals, Inc (XFOR). 6 reported Form 4/5 transactions since Sep 2024; latest on Feb 12, 2025. Located in BOSTON, MA.
Companies DiBiase Mary has filed insider reports for
- X4 Pharmaceuticals, Inc (XFOR): Officer, Chief Operating Officer
DiBiase Mary
CIK: 0001880179
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)3 (50.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)3 (50.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
XFOR
X4 Pharmaceuticals, Inc
Officer
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Feb 12, 2025XFOR
X4 Pharmaceuticals, Inc
AwardDirect650K shares- - Jan 24, 2025XFOR
X4 Pharmaceuticals, Inc
SaleDirect22.3K shares at avg. $0.45$10K - Jan 23, 2025XFOR
X4 Pharmaceuticals, Inc
AwardDirect61.2K shares- - Oct 7, 2024XFOR
X4 Pharmaceuticals, Inc
SaleDirect67.7K shares at avg. $0.57$38K - Oct 4, 2024XFOR
X4 Pharmaceuticals, Inc
AwardDirect230.6K shares- - Sep 9, 2024XFOR
X4 Pharmaceuticals, Inc
SaleDirect2.6K shares at avg. $0.66$2K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Feb 12, 2025 | XFOR X4 Pharmaceuticals, Inc | Award | 650,000 | - | - | Direct |
| Jan 24, 2025 | XFOR X4 Pharmaceuticals, Inc | Sale | 22,258 | $0.45 | $10,094 | Direct |
| Jan 23, 2025 | XFOR X4 Pharmaceuticals, Inc | Award | 61,178 | - | $0 | Direct |
| Oct 7, 2024 | XFOR X4 Pharmaceuticals, Inc | Sale | 67,695 | $0.57 | $38,329 | Direct |
| Oct 4, 2024 | XFOR X4 Pharmaceuticals, Inc | Award | 230,645 | - | $0 | Direct |
| Sep 9, 2024 | XFOR X4 Pharmaceuticals, Inc | Sale | 2,642 | $0.66 | $1,738 | Direct |
1-6 of 6 transactions